Nureca Limited has informed the Exchange regarding Re-Appointment of MGSG AND ASSOCIATES as Internal Auditor of the company w.e.f. April 01, 2026.
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nureca Limited reported Q4 FY26 standalone revenue of Rs 354.05 million with a loss of Rs 66.25 million, impacted by Rs 83.37 million fair value loss on investments. For full year FY26, revenue grew 28.4% to Rs 1,472.10 million from Rs 1,146.40 million, with the company returning to profit at Rs 2.97 million (vs loss of Rs 6.68 million in FY25). The Board approved appointment of Mr. Chander Kant as new CFO from June 27, 2026, replacing Mr. Naresh Gupta who resigned effective June 26, 2026 for better career opportunities. Multiple director appointments were approved: Ms. Smita Goyal as Additional Whole-time Director (June 1, 2026), and re-appointments of Mr. Aryan Goyal (CEO) and Mr. Saurabh Goyal (Managing Director) subject to shareholder approval. The Board approved Rs 100 crore incremental capex for manufacturing medical devices and healthcare products at Derabassi, Punjab, plus purchase of additional adjoining land for future expansion. The 10th AGM is scheduled for July 28, 2026.
The company achieved revenue growth and returned to profit in FY26, but Q4 weakness and investment losses raise concerns. The Rs 100 crore capex signals expansion in healthcare manufacturing, while the CFO transition and family-run board appointments may concern investors seeking independent governance.